E226: The AI Deal Scout: How Machine Intelligence Is Reshaping Biopharma Business Development
About this episode
The episode discusses how AI is transforming biopharma business development and deal scouting with insights from Smbat Rafayelyan.
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Smbat Rafayelyan, founder and CEO of Bioneex, about how AI is reshaping biopharma business development, deal scouting and asset evaluation. Business development has traditionally relied heavily on relationships, conferences, databases, analyst reports and manual search. But as therapeutic pipelines, publications, patent filings and global biotech activity expand, that old model is becoming harder to sustain. Smbat explains why teams that only rely on their network risk missing valuable assets before they even know they were available. The conversation explores how AI can act as a deal scout, helping biopharma and VC teams identify, structure and evaluate opportunities faster. Smbat explains how Bioneex allows biotech companies to submit non-confidential asset information, while AI extracts, validates and compares that data against external sources, curated databases and market intelligence. They also discuss where AI is most useful in the BD process. The aim is not to replace human judgement, but to reduce the overwhelming search space. If AI can narrow thousands of potential assets down to a small, relevant…
More episodes of AI For Pharma Growth
- E225: The 80% Nobody Talks About: Building AI Governance That Survives a Pharma Audit
- E224: The Diagnostic Room: The Financial Case Your CFO Actually Needs to See Before Approving Your AI Strategy
- E223: From Population Models to Personal Intelligence: Rethinking Biological Data
- E222: Why Most Pharma AI Will Fail Without This One Thing
Explore listener stats, chart rankings, contacts and more on the AI For Pharma Growth podcast page.